Trial Profile

Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia: a Randomized Phase II Trial Comparing FCR and a Chemo-free Combination of Venetoclax and Ibrutinib

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Venetoclax (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Acronyms ERADIC

18 Mar 2025 Status changed from active, no longer recruiting to completed.
29 Oct 2024 Planned End Date changed from 1 Jun 2026 to 1 Jan 2025.
12 Dec 2023 Interim results demonstrating intermediate safety data and MRD kinetics (M9 to M21) presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com